New York State Teachers Retirement System Has $4.75 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

New York State Teachers Retirement System boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 175.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 120,364 shares of the biopharmaceutical company's stock after buying an additional 76,600 shares during the quarter. New York State Teachers Retirement System owned 0.08% of TG Therapeutics worth $4,746,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after acquiring an additional 209,190 shares in the last quarter. Soleus Capital Management L.P. raised its stake in shares of TG Therapeutics by 5.8% in the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after acquiring an additional 146,702 shares in the last quarter. Clearbridge Investments LLC bought a new position in shares of TG Therapeutics in the 4th quarter valued at approximately $55,237,000. Northern Trust Corp raised its stake in shares of TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after acquiring an additional 120,785 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after acquiring an additional 84,904 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.64% of the company's stock.

TG Therapeutics Stock Performance

Shares of TGTX stock traded down $0.44 during trading on Tuesday, reaching $35.55. The company had a trading volume of 154,755 shares, compared to its average volume of 2,898,165. The firm's 50 day simple moving average is $36.65 and its two-hundred day simple moving average is $35.19. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. TG Therapeutics, Inc. has a one year low of $16.65 and a one year high of $46.48. The company has a market capitalization of $5.64 billion, a PE ratio of 148.53 and a beta of 1.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm's revenue was up 90.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.07) earnings per share. Sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.